Ziprasidone Hydrochloride Monohydrate
Ziprasidone Hydrochloride Monohydrate
Ziprasidone (marketed as Geodon, Zeldox and Zipwell) was the fifth atypical antipsychotic to gain approval (February 2001) in the United States.
Online Inquiry
| CAT# | 10-101-129 |
| CAS | 146939-27-7 (net), 138982-67-9 (hydrochloride monohydrate) |
| Synonyms/Alias | CP-88059; 5-(2-(4-(1,2-Benzisothiazol-3-yl)piperazinyl)ethyl)-6-chlorooxindole · HCl · H2O |
| M.F/Formula | C21H21ClN4OS·ClH·H2O |
| M.W/Mr. | 467.42 |
| Labeling Target | 5-hydroxytryptamine Receptor;
Dopamine Receptor |
| Application | Ziprasidone hydrochloride monohydrate is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia, acute mania and mixed states associated with bipolar disorder. Ziprasidone is also used off-label for depression, bipolar maintenance and PTSD. |
| Activity | Antagonist |
| Biological Activity | Ziprasidone (CP 88059) hydrochloride monohydrate, an antipsychotic agent, is an orally active combined 5-HT (serotonin) and dopamine receptor antagonist. Ziprasidone hydrochloride monohydrate has high affinity for rat (Ki: 3.4 nM)/human (2.5 nM) 5-HT1A receptors, 5-HT2A (0.42 nM), and dopamine D2 receptors (4.8 nM). Ziprasidone hydrochloride monohydrate is an inhibitor of norepinephrine reuptake. |
| Areas of Interest | Neurological Disease |
| Functions | Potassium channel regulator activity;
Virus receptor activity |
| Disease | Mixed bipolar I disorder
Schizophrenia
Bipolar disorder in remission |
| Target | 5-HT Receptor |
| Source# | Synthetic |
Organism | Human |
Write a review
Ask a question
My Review for Ziprasidone Hydrochloride Monohydrate
Required fields are marked with *
×
Ask a Question for Ziprasidone Hydrochloride Monohydrate
Required fields are marked with *
×
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
